COVID-19: Impact of and on Diabetes

被引：0
作者：
Jonathan Schofield
Lalantha Leelarathna
Hood Thabit
机构：
[1] Manchester University Hospitals NHS Foundation Trust,Manchester Diabetes Centre
[2] University of Manchester,Faculty of Biology Medicine and Health
来源：
Diabetes Therapy | 2020年 / 11卷
关键词：
Coronavirus; COVID-19; Diabetes; Hyperglycaemia; Service development;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Diabetes has been identified as a pre-existing health condition linked with worse outcomes following coronavirus disease 2019 infection. Here we explore the association between hyperglycaemia and more severe illness, the impact of the pandemic on diabetes service delivery, and the resultant opportunities for innovation.
引用
收藏
页码：1429 / 1435
页数：6
相关论文
共 49 条
[1]  
Bally L(2018)Closed-loop insulin delivery for glycemic control in noncritical care N Engl J Med 379 547-556
[2]  
Thabit H(2016)Anti-inflammatory effects of metformin irrespective of diabetes status Circ Res 119 652-665
[3]  
Hartnell S(2019)Glycaemic variability in diabetes: clinical and therapeutic implications Lancet Diabetes Endocrinol 7 221-230
[4]  
Cameron AR(2020)Clinical characteristics of coronavirus disease 2019 in China N Engl J Med 382 1708-1720
[5]  
Ceriello A(2020)Diabetes is a risk factor for the progression and prognosis of COVID-19 Diabetes Metab Res Rev. 88 1082-1088
[6]  
Monnier L(2003)Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels J Clin Endocrinol Metab 395 497-506
[7]  
Owens D(2020)Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 162 108142-211
[8]  
Guan WJ(2020)COVID-19 and diabetes: knowledge in progress Diabetes Res Clin Pract 351 201-3336
[9]  
Guo W(2016)The effect of short-term hyperglycemia on the innate immune system Am J Med Sci 17 R159-725
[10]  
Li M(2013)Feasibility of fully automated closed-loop glucose control using continuous subcutaneous measurements in critical illness: a randomized controlled trial Crit Care 36 3333-254
12345